ARCB vs BMRN · P/E 11, rev $4.18B vs P/E 40, rev $2.85B
ArcBest Corp (ARCB) versus Biomarin Pharmaceutical Inc (BMRN) — a side-by-side from cached financials, not a winner call.
ArcBest Corp (ARCB) is a trucking company listed on US.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Latest reported ARCB revenue for 2024-12-31 was $4.18B. Net income was $174.0M. Revenue was down 5.6% from 2023-12-31 to 2024-12-31. ARCB currently screens at market cap $1.94B and trailing P/E 11.2.
Latest reported BMRN revenue for 2024-12-31 was $2.85B. Net income was $426.9M. Revenue was up 18.0% from 2023-12-31 to 2024-12-31. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
ARCB currently screens at market cap $1.94B and trailing P/E 11.2. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Not investment advice. Open the ARCB and BMRN stock pages for the full models.
Not investment advice.